7/102 sources · 2 publishersUpdated Nov 4, 17:44 UTC
Danaher’s Cepheid receives FDA clearance for Xpert Hemorrhagic Fever Panel
Danaher’s diagnostics subsidiary Cepheid obtained FDA clearance for its Xpert Hemorrhagic Fever Panel, a PCR test that can detect four hemorrhagic fever viruses, including Ebola and Marburg, from a single sample. The clearance expands Danaher’s diagnostic portfolio and adds a new multiplex test to its offerings.
Why it matters
The company notes that the clearance could boost revenue and strengthen its market position in the medical diagnostics sector.
Key facts
- 1Cepheid, a Danaher subsidiary, received FDA approval for its Xpert Hemorrhagic Fever Panel. seekingalpha.com
- 2The panel detects four hemorrhagic fever viruses, such as Ebola and Marburg. finance.yahoo.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.